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Background: Sudden death is a leading cause of death in patients on maintenance hemodialysis therapy.
During hemodialysis sessions, the gradient between serum and dialysate levels results in rapid electrolyte
shifts, which may contribute to arrhythmias and sudden death. Controversies exist about the optimal elec-
trolyte concentration in the dialysate; specifically, it is unclear whether patient outcomes differ among those
treated with a dialysate potassium concentration of 3 mEq/L compared to 2 mEq/L.
Study Design: Prospective cohort study.
Setting & Participants: 55,183 patients from 20 countries in the Dialysis Outcomes and Practice Patterns
Study (DOPPS) phases 1 to 5 (1996-2015).
Predictor: Dialysate potassium concentration at study entry.
Outcomes: Cox regression was used to estimate the association between dialysate potassium concen-
tration and both all-cause mortality and an arrhythmia composite outcome (arrhythmia-related hospitalization
or sudden death), adjusting for potential confounders.
Results: During a median follow-up of 16.5 months, 24% of patients died and 7% had an arrhythmia
composite outcome. No meaningful difference in clinical outcomes was observed for patients treated with a
dialysate potassium concentration of 3 versus 2 mEq/L (adjusted HRs were 0.96 [95% CI, 0.91-1.01] for
mortality and 0.98 [95% CI, 0.88-1.08] for arrhythmia composite). Results were similar across predialysis
serum potassium levels. As in prior studies, higher serum potassium level was associated with adverse
outcomes. However, dialysate potassium concentration had only minimal impact on serum potassium level
measured predialysis (10.09 [95% CI, 0.05-0.14] mEq/L serum potassium per 1 mEq/L greater dialysate
potassium concentration).
Limitations: Data were not available for delivered (vs prescribed) dialysate potassium concentration and
postdialysis serum potassium level; possible unmeasured confounding.
Conclusions: In combination, these results suggest that approaches other than altering dialysate potas-
sium concentration (eg, education on dietary potassium sources and prescription of potassium-binding
medications) may merit further attention to reduce risks associated with high serum potassium levels.
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Dialysate Potassium, Serum Potassium, and MortalitySudden death is a leading cause of death in patientsrequiring hemodialysis (HD), with 27% of all
deaths attributable to arrhythmic mechanisms.1 In
thrice-weekly maintenance HD, these events tend to
cluster in the period just prior to the ﬁrst dialysis
session of the week, when ﬂuid overload and levels of
various uremic toxins are highest, and in the period
during and immediately following HD sessions.2-4
Although a multiplicity of factors contribute to sud-
den death, it is speculated that the increased risk
during and immediately following the HD session is
associated with large ﬂuid and electrolyte shifts that
occur during this time.3
Hyperkalemia is common in patients with kidney
failure due to diminished renal potassium excretion
causing disturbances in heart rhythm and cardiac ar-
rest in extreme cases.5,6 High predialysis serum po-
tassium level is recognized as a risk factor for sudden
death and all-cause mortality in HD patients.7,8 Po-
tassium has the potential to move freely across the
dialyzer membrane during the HD session, typically
being transferred from a patient’s blood into the
dialysate.9 Dialysate potassium concentration is a
modiﬁable factor that can alter serum potassium
concentrations throughout the HD session and thus
potentially affects the risk for arrhythmias and cardiac
arrest.10 Results of studies examining dialysate po-
tassium effects on sudden death and all-cause mor-
tality have been mixed. Kovesdy et al7 advised that
hyperkalemic patients with a lower dialysate potas-
sium concentration bath may have better survival,
whereas 2 large case-control studies investigated
sudden death events occurring during dialysis and
concluded that there was an increased risk for sudden
death for patients dialyzing with dialysate potassium
concentrations of 1 mEq/L or even 0 mEq/L.11,12
Although no recommendation for dialysate
potassium concentrations has been provided in the
NKF-KDOQI (National Kidney Foundation–Kidney
Disease Outcomes Quality Initiative) cardiovascular
disease guideline,13 several recent reviews are in
agreement that dialysate potassium concentration
, 2 mEq/L should be avoided, particularly in pa-
tients with high predialysis potassium levels, to avoid
a rapid decrease in plasma potassium levels.6,14-18
Accordingly, anecdotal reports indicate that the use
of dialysate potassium concentrations , 2 mEq/L has
become increasingly rare. This prompted us to
investigate whether a dialysate potassium concentra-
tion of 2 mEq/L was still too low, in comparison to a
higher dialysate potassium concentration of 3 mEq/L.
In the absence of conclusive results, many clinicians’
dialysate potassium prescriptions often aim to keep
serum potassium levels within an “acceptable” range.
Some nephrologists make decisions qualitatively basedAm J Kidney Dis. 2017;69(2):266-277on clinical judgment and experience, others anecdotally
use the “rule of 7” and prescribe dialysate potassium
concentrations to make the sum of dialysate potassium
and predialysis serum potassium level approximately
7,19 whereas some facilities’ medical staff elect to
provide a uniform dialysate potassium concentration to
all patients. However, optimal prescription practices are
unknown: treating with lower dialysate potassium
concentrations promotes greater intradialytic potassium
ﬂux and increases the likelihood of hypokalemia;
conversely, treating with higher dialysate potassium
concentrations may predispose patients to hyper-
kalemia. The former may be worsened among patients
with already low predialysis serum potassium levels,
and the latter, among patients with high predialysis
serum potassium levels. Furthermore, treating patients
with a high predialysis serum potassium level with a
low dialysate potassium concentration may cause a
rapid intradialytic shift in potassium during the ﬁrst
hour of dialysis. Thus, there is reason to speculate that
the effect of dialysate potassium concentration may be
modiﬁed based on patients’ predialysis serum potas-
sium levels.
A previous Dialysis Outcomes and Practice Patterns
Study (DOPPS) analysis20 observed associations be-
tween sudden death and various modiﬁable practices:
low treatment time, low Kt/V, high ultraﬁltration
volume, and low dialysate potassium concentration.
Given more recent trends toward higher dialysate po-
tassium concentrations and the lack of clear evidence
across studies comparing the 2 most commonly used
dialysate potassium prescriptions (2 vs 3 mEq/L), we
revisited the issue of dialysate potassium concentration
and clinical outcomes using a larger and more
contemporary cohort of patients. In this study, we
leveraged data from the international cohort of in-
center HD patients in the DOPPS to assess the risks
of different dialysate potassium prescriptions overall
and among patients with different serum potassium
levels. We also examined associations between pre-
dialysis serum potassium levels and outcomes, as well
as association between dialysate potassium concen-
trations and serum potassium levels.
METHODS
Data Source
The DOPPS (www.dopps.org) is an international prospective
cohort study of patients 18 years or older treated with in-center HD.
The study is designed to observe patients over time and correlate
practices and outcomes in different medical settings around the
world to help researchers and clinicians identify best practices and
other modiﬁable characteristics that improve dialysis patients’
lives. Patients were randomly selected from national samples of
dialysis facilities within each country.21,22 In this analysis, data
from participants in DOPPS phase 1 (1996-2001), phase 2 (2002-
2004), phase 3 (2005-2008), phase 4 (2009-2011), and phase 5267
Karaboyas et al(2012-2015) were used. Participating countries included France,
Germany, Italy, Japan, Spain, the United Kingdom, and the United
States in phases 1 to 5; Australia and New Zealand, Belgium,
Canada, and Sweden in phases 2 to 5; and the Gulf Cooperation
Council (including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia,
and United Arab Emirates), China, Russia, and Turkey in phase 5.
Study approval in the United States was obtained by a central
institutional review board (approval number 98004-19). Additional
study approval and patient consent were obtained as required by
national and local ethics committee regulations.
Data for demographics, comorbid conditions, laboratory values
(single most recent value), and prescriptions were abstracted from
medical records using uniform and standardized data collection
tools. Mortality and hospitalization events and the primary causes
of these events were collected during study follow-up. Patients
with predialysis serum potassium and dialysate potassium data
available at DOPPS entry (baseline: single most recent value at
study entry) were eligible for this analysis. Patients in Japan were
excluded from analyses of clinical outcomes due to lack of vari-
ation in the primary exposure variable (dialysate potassium of 2
mEq/L in all patients), but were included in descriptive ﬁgures to
illustrate the within- and across-country variation. See Figure 1 for
eligibility criteria details.
Statistical Analysis
To estimate the association between baseline predialysis serum
potassium level and all-cause mortality, we used Cox regression
stratiﬁed by DOPPS phase and country, and by US large dialysis
organization when applicable. Proportional hazards were
conﬁrmed by examination of log-log survival plots and by testing
the interaction between log-time and the exposure of interest. We
accounted for facility clustering using robust sandwich covariance
estimators. We categorized serum potassium level, with 4.0 to 5.0
mEq/L (50% of patients) as the reference group. Models were
analyzed both unadjusted and adjusted for the following baseline
covariates: age, sex, dialysis vintage, the 13 comorbid conditions
listed in Table 1, vascular access, body mass index, normalized
protein catabolic rate (nPCR), serum albumin level, calcium level,
bicarbonate level, phosphorus level (linear and quadratic term toN=77,211 patients in DOPPS phases 1-5*
N=70,597 patients used in figures showing 
distribution of SK and DK
6,614 patients missing DK or SK data at study entry
N=55,183 patients used in primary analysis of 
all-cause mortality
11,580 patients in Japan where DK=2 mEq/L was uniform
3,834 patients with no follow-up information after baseline
N=45,511 patients used in analyses of 
arrhythmia composite outcomes
9,672 patients in facilities not reporting cause of events
Figure 1. Flow chart of Dialysis Outcomes and Practice Pat-
terns Study (DOPPS) patients eligible for analysis. *Current as
of September 29, 2015. Abbreviations: DK, dialysate potassium;
SK, serum potassium.
268account for U-shaped association), dialysate bicarbonate concen-
tration, hemoglobin level, treatment time, and Kt/V. Time at risk
started at study enrollment and ended at the time of death, 7 days
after leaving the facility due to transfer or change in kidney
replacement therapy modality, loss to follow-up, transplantation,
or end of study phase (whichever event occurred ﬁrst). The sec-
ondary study outcome was an arrhythmia composite deﬁned as
time to the ﬁrst of any of the following events: death due to either
hyperkalemia, hypokalemia, cardiac arrhythmia, or cardiac arrest
(cause unknown); inpatient hospitalization due to atrial ﬁbrillation
or other arrhythmia; or a procedure for cardioversion or automatic
implantable cardioverter-deﬁbrillator or pacemaker placement. We
excluded from analyses of the composite outcome facilities lack-
ing information for causes of death and hospitalization.
Similarly, we used Cox regression to estimate the associations
of baseline dialysate potassium concentration with all-cause mor-
tality and the arrhythmia composite outcome, both unadjusted and
adjusted as aforementioned. Dialysate potassium concentration
was categorized into 3 groups, with 2.0 to 2.5 mEq/L as the
reference. We also estimated the effect of dialysate potassium
concentration as a continuous variable using instrumental variable
analyses, performed as described in the following paragraph, but
modiﬁed to use a Cox model in the second stage. We then assessed
whether the association between dialysate potassium concentration
and clinical outcomes was modiﬁed by predialysis serum potas-
sium level. Because dialysate potassium concentrations of 2.0 and
3.0 mEq/L are by far the most common prescriptions in use, we
restricted this comparison to patients with either dialysate potas-
sium concentrations of 2.0 (reference) or 3.0 mEq/L and tested the
association among 4 subgroups of patients based on predialysis
serum potassium level.
To assess the association between dialysate potassium concen-
tration and predialysis serum potassium level, we ﬁrst modeled
serum potassium level as the outcome variable in a linear mixed
model to account for facility clustering, treating dialysate potas-
sium concentration as a continuous exposure variable. We
modeled the relationship adjusting for DOPPS phase and country
only and subsequently adjusting as aforementioned. Because we
suspected a large degree of confounding by indication (ie, patients
with lower predialysis serum potassium being individualized to
receive a higher dialysate potassium concentration), we performed
an instrumental variable 2-stage least squares analysis to account
for this bias. Although violations of other assumptions of instru-
mental variable analyses cannot be formally assessed, we
demonstrated the strength of the DOPPS facility as the instru-
ment23: F5 13.6. Additionally, we observed better balance across
patient characteristics by quartile of facility mean dialysate po-
tassium concentration than by patient dialysate potassium con-
centration (Table S1, available as online supplementary material).
Whereas using facility as the instrument can be an effective
strategy to address unmeasured patient-level confounding, group-
level confounding can also be a concern.24 We thus additionally
adjusted for 6 dialysis unit practices: the percentage of patients in a
facility with a catheter, with single-pool Kt/V , 1.2, with albumin
level , 3.5 g/dL, and with phosphorus level $ 5.5 mg/dL, and
mean within-facility hemoglobin levels and dialysate bicarbonate
concentrations. Because potassium-binding resins are also likely
prescribed on the basis of serum potassium level, we treated po-
tassium resins as an additional endogenous variable to simulta-
neously account for the confounding by indication caused by
dialysate potassium concentration and potassium-binding resin
use.25 To test the robustness of the instrumental variable ﬁndings,
sensitivity analyses were conducted using linear mixed models
with (1) crude facility mean dialysate potassium concentration as
the exposure and (2) restricting to facilities prescribing a uniform
dialysate potassium concentration to $ 90% of patients, a strategy
similar to that used by Hecking et al26 for dialysate sodium studies.Am J Kidney Dis. 2017;69(2):266-277
Table 1. Patient Characteristics by Predialysis Serum Potassium
Serum Potassium, mEq/L
,4.0 (n 5 6,300 [11%]) 4.0-5.0 (n 5 27,525 [50%]) 5.1-6.0 (n 5 16,959 [31%]) .6.0 (n 5 4,399 [8%])
Demographics
Age, y 63.8 6 15.2 63.0 6 15.2 61.8 6 15.3 60.4 6 15.3
Male sex 56% 58% 59% 56%
Black race 20% 17% 11% 7%
Dialysis vintage, y 2.0 6 3.7 2.9 6 4.4 4.06 5.2 4.56 5.4
Hemodialysis-related characteristics
Central venous catheter use 47% 34% 26% 25%
Single-pool Kt/V 1.41 6 0.35 1.46 6 0.34 1.46 6 0.33 1.44 6 0.34
Session duration, min 2196 37 2256 38 230 6 39 2336 39
Dialysate potassium, mEq/L 2.4 6 0.7 2.2 6 0.6 2.16 0.6 2.06 0.6
Laboratory and biometric measurements
Body mass index, kg/m2 26.66 6.4 26.66 6.3 26.0 6 6.0 25.2 6 5.5
Predialysis SBP, mm Hg 1446 24 1456 23 145 6 23 1456 23
Hemoglobin, g/dL 10.76 1.6 11.06 1.5 11.2 6 1.6 11.2 6 1.7
nPCR, g/kg/d 0.85 6 0.24 0.95 6 0.25 1.04 6 0.26 1.10 6 0.27
Serum creatinine, mg/dL 6.6 6 2.8 7.7 6 3.0 8.96 2.9 9.76 3.0
Serum albumin, g/dL 3.46 6 0.61 3.65 6 0.53 3.76 6 0.51 3.81 6 0.52
WBC count, 3103 cells/mL 7.6 6 2.9 7.3 6 2.5 7.26 2.4 7.46 2.5
Serum bicarbonate, mEq/L 23.96 4.0 22.96 3.6 22.1 6 3.6 21.3 6 3.8
Serum calcium, mg/dL 8.8 6 0.9 9.0 6 0.9 9.16 0.9 9.26 0.9
Serum phosphorus, mg/dL 4.7 6 1.7 5.2 6 1.7 5.66 1.8 6.06 2.0
Serum potassium, mEq/L 3.6 6 0.3 4.5 6 0.3 5.56 0.3 6.56 0.4
Medications
ACE inhibitor 19% 23% 25% 23%
ARB 12% 13% 15% 15%
Diuretic 35% 30% 24% 18%
Potassium-binding resin 4% 6% 11% 17%
Comorbid conditions
Coronary artery disease 43% 42% 41% 38%
Cancer (nonskin) 13% 13% 12% 11%
Other cardiovascular disease 31% 30% 32% 31%
Cerebrovascular disease 17% 16% 15% 14%
Heart failure 36% 33% 32% 30%
Diabetes 48% 46% 40% 34%
Gastrointestinal bleeding 7% 5% 5% 5%
Hypertension 84% 84% 84% 82%
Lung disease 13% 13% 13% 13%
Neurologic disease 11% 10% 10% 10%
Psychiatric disorder 21% 18% 18% 19%
Peripheral vascular disease 27% 26% 26% 25%
Recurrent cellulitis, gangrene 9% 9% 9% 9%
Note: Values for categorical variables are given as proportion; for continuous variables, as mean 6 standard deviation. N 5 55,183
patients who were included in all-cause mortality analyses. Conversion factors for units: calcium in mg/dL to mmol/L, 30.2495;
creatinine in mg/dL to mmol/L, 388.4; phosphorus in mg/dL to mmol/L, 30.3229.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; nPCR, normalized protein catabolic rate;
SBP, systolic blood pressure; WBC, white blood cell.
Dialysate Potassium, Serum Potassium, and MortalityWe assumed the data were missing at random; missing covariate
values were addressed by the Sequential Regression Multiple
Imputation Method using IVEware.27,28 Results from 5 such
imputed data sets were combined for the ﬁnal analysis using
Rubin’s formula.29 Largely due to the high number of model
covariates, 67% of patients were missing data for at least one
adjustment covariate. The proportion of missing data was , 10%
for all variables used for covariate adjustment, with the exception
of nPCR (35%), Kt/V (32%), serum bicarbonate level (22%), andAm J Kidney Dis. 2017;69(2):266-277dialysate bicarbonate concentration (18%). All analyses were
conducted using SAS software, version 9.4 (SAS Institute Inc).
RESULTS
Predialysis Serum Potassium Levels
The distribution of serum potassium levels, by
country, in DOPPS phase 5 is shown in Figure 2A.269
Figure 2. (A) Predialysis serum potassium (K) distribution by country in Dialysis Outcomes and Practice Patterns Study (DOPPS)
phase 5 (2012-2015). N5 17,815 patients. Abbreviations: ANZ, Australia and New Zealand; Bel, Belgium; Can, Canada; Chi, China;
Fra, France; GCC, Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates); Ger, Germany;
Ita, Italy; Jpn, Japan; Rus, Russia; Spa, Spain; Swe, Sweden; Tur, Turkey; UK, United Kingdom; US, United States. (B) Temporal
trends in predialysis serum potassium by DOPPS region (1996-2015). N 5 67,263 patients. DOPPS phase 1: 1996-2001, phase 2:
2002-2004, phase 3: 2005-2008, phase 4: 2009-2011, phase 5: 2012-2015. Note that countries recently joining the DOPPS in phase
5 (N 5 3,334 patients) are not represented in this figure.
Karaboyas et alMean serum potassium level was highest in Russia
(5.3 mEq/L) and lowest in the United States (4.6
mEq/L). Trend analyses (Fig 2B) demonstrated that
serum potassium level has decreased during the past
20 years in Europe, Australia, New Zealand, and
Japan. In North America, mean serum potassium level270remained fairly constant. In each country, serum po-
tassium levels collected at the ﬁrst HD session of the
week (Monday/Tuesday) were slightly higher than
levels collected midweek (Wednesday/Thursday); the
difference ranged from 0.01 mEq/L in China to 0.19
mEq/L in Germany.Am J Kidney Dis. 2017;69(2):266-277
Dialysate Potassium, Serum Potassium, and MortalityDialysate Potassium Prescription
Figure 3A shows dialysate potassium prescription
patterns in each DOPPS country during phase 5
(2012-2015). Dialysate potassium concentration of
2.0 to 2.5 mEq/L was the most common prescription
worldwide, prescribed to 75% of patients in the
United States and . 99% of patients in Japan.
Dialysate potassium concentration was highest in
Germany, where a dialysate potassium concen-
tration $ 3.0 mEq/L was used in 75% of patients.
Prescription of dialysate potassium concentration of
1.0 to 1.5 mEq/L was primarily concentrated in
Spain. The practice pattern of prescribing a uniform
dialysate potassium concentration to $ 90% of pa-
tients in the facility varied widely across countries
(table insert below Fig 3A). In addition to Japan,
uniform dialysate potassium prescription of 2.0
mEq/L was common in China (84% of facilities) and
Turkey (79%). In contrast, uniform dialysate potas-
sium prescription was less common in the United
States (27% of facilities) and rarely used in Germany
(5%) and Canada (5%). Trend analyses (Fig 3B)
show that dialysate potassium concentration has
been steadily increasing in Europe/Australia and
New Zealand across the DOPPS phases. In North
America, recent trends show a decline in the pro-
portion of patients prescribed dialysate potassium
concentrations , 2 mEq/L, down to 5% in phase 5.
Study Sample Characteristics
Descriptive patient characteristics, by serum po-
tassium and dialysate potassium categories, are shown
in Tables 1 and 2. Patients in the lowest serum po-
tassium group differed from patients in the highest
serum potassium group in many ways; for instance,
they were older and had a shorter dialysis vintage,
more catheter use, lower nPCR, and lower creatinine,
albumin, and phosphorus levels. Patient characteris-
tics also differed across dialysate potassium pre-
scriptions; for instance, those in the highest dialysate
potassium group were older; had a shorter dialysis
vintage, more catheter use, lower nPCR, lower
creatinine and albumin levels, and lower serum po-
tassium levels; and were more likely to have been
prescribed a diuretic.
Serum Potassium and Clinical Outcomes
Among the 55,183 patients from DOPPS phases 1
to 5 included in outcome analyses, median follow-up
was 16.5 (interquartile range, 8.1-25.5) months and
13,114 (24%) died during follow-up, resulting in a
mortality rate of 16.1/100 patient-years. As shown in
Table 3, compared with the reference group of serum
potassium level of 4.0 to 5.0 mEq/L, lower serum
potassium level, but not higher serum potassium
level, was associated with mortality in unadjustedAm J Kidney Dis. 2017;69(2):266-277analysis. However, after comprehensive multivariable
adjustment, particularly for nutritional indicators
(Table S2), the shape of the association changed, now
with higher but not lower serum potassium level be-
ing associated with mortality. Among the 45,511
patients eligible for the cause-speciﬁc outcome anal-
ysis, 3,300 (7%) had an arrhythmia composite event
during follow-up. The adjusted association between
serum potassium level and the composite arrhythmia
outcome appeared approximately monotonic, with
increased risk for patients with higher serum potas-
sium levels (Table 3).
Dialysate Potassium and Clinical Outcomes
We observed higher unadjusted mortality for pa-
tients with high dialysate potassium concentrations
(Table 4). After comprehensive adjustment for
potential confounders, the hazard ratio (HR) for
mortality was 0.95 (95% conﬁdence interval [CI],
0.90-1.00) for patients treated with dialysate potas-
sium concentrations of 3.0 to 4.0 mEq/L and 1.04
(95% CI, 0.97-1.11) for patients treated with dialysate
potassium concentrations of 1.0 to 1.5 mEq/L,
compared to the reference group (2.0-2.5 mEq/L).
Analysis of the arrhythmia composite outcome is also
shown in Table 4. Using instrumental variable
methods, the HR per 1-mEq/L higher dialysate po-
tassium concentration was 0.99 (95% CI, 0.92-1.07)
for all-cause mortality and 0.96 (95% CI, 0.82-1.12)
for the arrhythmia composite outcome.
In Table 5, we show the associations with clinical
outcomes of dialysate potassium concentration of 3.0
versus 2.0 mEq/L at various predialysis serum po-
tassium levels. Again, the estimated differences in
mortality risk were minimal, with HRs ranging from
0.94 to 1.03 across the 4 serum potassium subgroups,
with no discernible pattern. Similarly, we found no
associations between dialysate potassium concentra-
tion and the arrhythmia composite outcome in any of
the serum potassium strata. Furthermore, there was
no evidence for effect modiﬁcation of dialysate
potassium concentration by serum potassium
level for all-cause mortality (P for interaction 5 0.7)
or the arrhythmia composite outcome (P for
interaction 5 0.7).
Association Between Dialysate and Serum Potassium
In a linear regression model adjusted for
only DOPPS phase and country, we observed an
inverse association between dialysate potassium
concentration and predialysis serum potassium level
(20.35 [95% CI, 20.37 to 20.34] mEq/L of serum
potassium per 1-mEq/L greater dialysate potassium).
After multivariate adjustment for confounders, the
inverse association remained (20.25; 95% CI, 20.26
to 20.24). However, in an instrumental variable271
Figure 3. (A) Dialysate potassium (K) distribution by country in Dialysis Outcomes and Practice Patterns Study (DOPPS) phase 5
(2012-2015). *Indicates proportion of facilities (Fac) prescribing a uniform dialysate potassium level to $90% of patients. N 5 17,815
patients. Abbreviations: A/NZ, Australia and New Zealand; Bel, Belgium; Can, Canada; Chi, China; Fra, France; GCC, Gulf Cooper-
ation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates); Ger, Germany; Ita, Italy; Jpn, Japan; Rus,
Russia; Spa, Spain; Swe, Sweden; Tur, Turkey; UK, United Kingdom; US, United States. In the dialysate potassium 3.0 to 4.0 group,
89% of patients had dialysate potassium concentrations of 3.0 mEq/L; in the dialysate potassium 2.0 to 2.5 group, 98% of patients had
dialysate potassium concentrations of 2.0 mEq/L; the dialysate potassium 1.0 to 1.5 group was primarily concentrated in Spain, where
98% of patients prescribed dialysate potassium concentrations of 1.0 to 1.5 had dialysate potassium concentrations of 1.5 mEq/L; else-
where, 75% of patients in the 1.0 to 1.5 group had dialysate potassium concentrations of 1.0 mEq/L. (B) Temporal trends in dialysate
potassium by DOPPS region (1996-2015). N 5 67,263 patients. DOPPS phase 1: 1996-2001, phase 2: 2002-2004, phase 3: 2005-
2008, phase 4: 2009-2011, phase 5: 2012-2015. Note that countries recently joining the DOPPS in phase 5 (N5 3,334 patients)
are not represented in this figure.
272 Am J Kidney Dis. 2017;69(2):266-277
Karaboyas et al
Table 2. Patient Characteristics by Dialysate Potassium
All (N 5 55,183)
Dialysate Potassium, mEq/L
1.0-1.5 (n 5 8,109 [15%]) 2.0-2.5 (n 5 33,497 [61%]) 3.0-4.0 (n 5 13,577 [25%])
Demographics
Age, y 62.5 6 15.3 61.4 6 15.4 61.6 6 15.4 65.5 6 14.5
Male sex 58% 60% 58% 56%
Black race 15% 6% 18% 11%
Dialysis vintage, y 3.3 6 4.7 4.36 5.5 3.56 4.8 2.16 3.7
Hemodialysis-related characteristics
Central venous catheter use 32% 26% 30% 41%
Single-pool Kt/V 1.45 6 0.34 1.46 6 0.33 1.46 6 0.33 1.42 6 0.35
Session duration, min 2266 39 227 6 39 227 6 37 225 6 43
Dialysate potassium, mEq/L 2.2 6 0.6 1.36 0.3 2.06 0.1 3.16 0.3
Laboratory and biometric measurements
Body mass index, kg/m2 26.36 6.2 25.5 6 5.5 26.4 6 6.3 26.6 6 6.1
Predialysis SBP, mm Hg 1456 23 144 6 23 146 6 23 142 6 23
Hemoglobin, g/dL 11.16 1.6 11.3 6 1.6 11.0 6 1.6 10.9 6 1.6
nPCR, g/kg/d 0.98 6 0.26 1.07 6 0.26 0.98 6 0.26 0.91 6 0.25
Serum creatinine, mg/dL 8.1 6 3.1 8.76 2.9 8.56 3.1 6.96 2.8
Serum albumin, g/dL 3.68 6 0.54 3.74 6 0.51 3.69 6 0.53 3.59 6 0.58
WBC count, 3103 cells/mL 7.3 6 2.5 7.26 2.4 7.36 2.6 7.46 2.6
Serum bicarbonate, mEq/L 22.76 3.7 22.7 6 3.5 22.7 6 3.7 22.8 6 3.8
Serum calcium, mg/dL 9.0 6 0.9 9.26 0.9 9.06 0.9 8.96 0.9
Serum phosphorus, mg/dL 5.3 6 1.8 5.46 1.8 5.46 1.8 5.16 1.7
Serum potassium, mEq/L 4.9 6 0.8 5.16 0.8 4.96 0.8 4.76 0.8
Medications
ACE inhibitor 23% 21% 23% 24%
ARB 14% 14% 13% 14%
Diuretic 28% 16% 24% 43%
Potassium-binding resin 8% 11% 9% 6%
Comorbid conditions
Coronary artery disease 42% 39% 41% 46%
Cancer (nonskin) 12% 12% 12% 15%
Other cardiovascular disease 31% 33% 28% 35%
Cerebrovascular disease 15% 15% 15% 17%
Heart failure 33% 31% 33% 33%
Diabetes 43% 35% 44% 47%
Gastrointestinal bleeding 6% 5% 5% 6%
Hypertension 84% 83% 83% 85%
Lung disease 13% 14% 12% 15%
Neurologic disease 10% 10% 10% 11%
Psychiatric disorder 18% 19% 18% 19%
Peripheral vascular disease 26% 27% 25% 29%
Recurrent cellulitis, gangrene 9% 9% 8% 9%
Note: Values for categorical variables are given as proportion; for continuous variables, as mean 6 standard deviation. N 5 55,183
patients who were included in all-cause mortality analyses. In the dialysate potassium 3.0 to 4.0 group, 89% of patients had dialysate
potassium concentrations of 3.0 mEq/L; in the dialysate potassium 2.0 to 2.5 group, 98% of patients had dialysate potassium con-
centrations of 2.0 mEq/L; the dialysate potassium 1.0 to 1.5 group was primarily concentrated in Spain, where 98% of patients pre-
scribed dialysate potassium concentrations of 1.0 to 1.5 had dialysate potassium concentrations of 1.5 mEq/L; elsewhere, 75% of
patients in the 1.0 to 1.5 group had dialysate potassium concentrations of 1.0 mEq/L. Conversion factors for units: calcium in mg/dL to
mmol/L, 30.2495; creatinine in mg/dL to mmol/L, 388.4; phosphorus in mg/dL to mmol/L, 30.3229.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; nPCR, normalized protein catabolic rate;
SBP, systolic blood pressure; WBC, white blood cell.
Dialysate Potassium, Serum Potassium, and Mortalityanalysis, we observed a weak positive association
between dialysate potassium concentration and serum
potassium level (10.09 [95% CI, 10.05 to 10.14]
mEq/L of serum potassium per 1-mEq/L greater
dialysate potassium). Sensitivity analyses (1) usingAm J Kidney Dis. 2017;69(2):266-277facility mean dialysate potassium concentration as the
exposure and (2) restricting to facilities that pre-
scribed a uniform dialysate potassium concentration
to $ 90% of patients resulted in ﬁndings consistent
with the instrumental variable analysis.273
Table 3. Associations Between Predialysis Serum Potassium and Clinical Outcomes
Serum Potassium No. of Patients (%)
All-Cause Mortality Arrhythmia Compositea
Unadjusted Adjustedb Unadjusted Adjustedb
,4.0 mEq/L 6,300 (11) 1.18 (1.12-1.24) 1.03 (0.97-1.09) 0.99 (0.88-1.11) 0.94 (0.83-1.05)
4.0-5.0 mEq/L 27,525 (50) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
5.1-5.5 mEq/L 10,700 (19) 0.95 (0.91-0.99) 1.02 (0.97-1.07) 0.97 (0.89-1.07) 1.00 (0.91-1.10)
5.6-6.0 mEq/L 6,259 (11) 1.02 (0.96-1.08) 1.13 (1.06-1.20) 1.05 (0.95-1.17) 1.07 (0.96-1.20)
.6.0 mEq/L 4,399 (8) 1.00 (0.93-1.07) 1.12 (1.04-1.21) 1.16 (1.02-1.32) 1.21 (1.05-1.38)
Note: Unless otherwise indicated, values are given as hazard ratio (95% confidence interval). Cox models stratified by Dialysis
Outcomes and Practice Patterns Study phase, country, US large dialysis organization (all-cause mortality only), and accounted for
facility clustering.
aArrhythmia composite includes sudden death or arrhythmia-related hospitalizations. For the arrhythmia composite outcome, 45,511
patients (3,300 events; 7%) were eligible for the analysis after excluding facilities for which cause of death and/or hospitalization was
not obtained.
bAdjustments: age, sex, dialysis vintage, 13 comorbid conditions, vascular access, body mass index, albumin level, normalized
protein catabolic rate, serum calcium level, serum phosphorus level, serum phosphorus squared, serum bicarbonate level, dialysate
bicarbonate concentration, hemoglobin level, session duration, and Kt/V.
Karaboyas et alDISCUSSION
In the DOPPS, a large international prospective
cohort study of HD patients in which there were
considerable variations in predialysis serum potas-
sium levels and practice patterns of dialysate potas-
sium prescription, high serum potassium level was
associated with increased all-cause mortality and
arrhythmia/sudden death after multivariable adjust-
ment. When comparing the 2 most common dialysate
potassium prescriptions (dialysate potassium concen-
tration of 3 vs 2 mEq/L), we did not ﬁnd evidence of
differential risk for adverse events, overall or at any
level of predialysis serum potassium level. We also
observed only a minimal impact of dialysate potas-
sium concentration on predialysis serum potassium
level in an instrumental variable analysis designed to
minimize confounding by indication.
Consistent with prior studies, we observed an
elevated risk for both all-cause mortality and an
arrhythmia composite outcome in patients with highTable 4. Associations Between Dialysat
Dialysate Potassium No. of Patients (%)
All-Cause
Unadjusted
1.0-1.5 mEq/L 8,114 (15) 0.96 (0.90-1.03)
2.0-2.5 mEq/L 33,017 (61) 1.00 (reference)
3.0-4.0 mEq/L 13,405 (25) 1.13 (1.07-1.18)
Note: Unless otherwise indicated, values are given as hazard ra
Outcomes and Practice Patterns Study phase, country, US large di
facility clustering.
aArrhythmia composite includes sudden death or arrhythmia-related
patients (3,300 events; 7%) were eligible for the analysis after exclud
not obtained.
bAdjustments: age, sex, dialysis vintage, 13 comorbid conditions
protein catabolic rate, serum calcium level, serum phosphorus level,
bicarbonate concentration, hemoglobin level, session duration, and
274serum potassium levels. Similar to Kovesdy et al,7 the
strong unadjusted association between hypokalemia
and adverse events was substantially confounded and
mostly attenuated by adjustment for case-mix and
indicators of malnutrition because a very low pre-
dialysis serum potassium level is more characteristic
of patients in generally poor health.
The use of dialysate potassium concentrations
, 2 mEq/L has declined across study phases in North
America and Europe. In the most recent DOPPS
phase (2012-2015), the proportion of patients with
dialysate potassium concentrations , 2 mEq/L was
down to 5% in North America and 16% in Europe/
Australia and New Zealand (only 6% in Europe/
Australia and New Zealand outside of Spain). Thus,
analyses of dialysate potassium concentrations of 1.0
to 1.5 mEq/L compared to 2 mEq/L may be limited in
scope and generalizability. Because dialysate potas-
sium concentrations of 2 or 3 mEq/L are the most
frequent prescriptions and given the lack of data fore Potassium and Clinical Outcomes
Mortality Arrhythmia Compositea
Adjustedb Unadjusted Adjustedb
1.04 (0.97-1.11) 1.09 (0.95-1.24) 1.14 (1.00-1.30)
1.00 (reference) 1.00 (reference) 1.00 (reference)
0.95 (0.90-1.00) 1.05 (0.96-1.15) 0.95 (0.86-1.04)
tio (95% confidence interval). Cox models stratified by Dialysis
alysis organization (all-cause mortality only), and accounted for
hospitalizations. For the arrhythmia composite outcome, 45,511
ing facilities for which cause of death and/or hospitalization was
, vascular access, body mass index, albumin level, normalized
serum phosphorus squared, serum bicarbonate level, dialysate
Kt/V.
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Table 5. Associations Between Dialysate Potassium and Clinical Outcomes by Predialysis Serum Potassium Concentration
All Patients
Predialysis Serum Potassium
,4.0 mEq/L 4.0-5.0 mEq/L 5.1-6.0 mEq/L .6.0 mEq/L
All-cause mortality: Dialysate potassium
3.0 vs 2.0 mEq/L (reference)
0.96 (0.91-1.01) 1.03 (0.91-1.17) 0.96 (0.90-1.03) 0.94 (0.85-1.03) 0.97 (0.78-1.20)
Arrhythmia composite: Dialysate potassium
3.0 vs 2.0 mEq/L (reference)
0.98 (0.88-1.08) 1.13 (0.86-1.47) 0.91 (0.80-1.04) 1.06 (0.89-1.27) 1.15 (0.81-1.62)
Note: Values are given as hazard ratio (95% confidence interval). Cox models stratified by Dialysis Outcomes and Practice Patterns
Study phase, country, US large dialysis organization (all-cause mortality only), and accounted for facility clustering. Arrhythmia
composite includes sudden death or arrhythmia-related hospitalizations. Number of patients (events) in all-cause mortality analyses:
6,300 (1,642) for serum potassium level , 4.0, 27,525 (6,473) for serum potassium level of 4.0 to 5.0, 16,959 (3,985) for serum
potassium level of 5.0 to 6.0, 4,399 (1,014) for serum potassium level . 6.0 mEq/L. Number of patients (events) in arrhythmia
composite analyses: 5,105 (350) for serum potassium level , 4.0, 21,997 (1,607) for serum potassium level of 4.0 to 5.0, 14,428
(1,039) for serum potassium level of 5.0 to 6.0, 3,981 (304) for serum potassium level . 6.0 mEq/L. Adjustments: age, sex, dialysis
vintage, 13 comorbid conditions, vascular access, body mass index, albumin level, normalized protein catabolic rate, serum calcium
level, serum phosphorus level, serum phosphorus squared, serum bicarbonate level, dialysate bicarbonate concentration, hemoglobin
level, session duration, and Kt/V.
Dialysate Potassium, Serum Potassium, and Mortalitytheir comparative impact on clinical outcomes, we
focused analyses on these 2 dialysate potassium
concentrations.
Prior results linking dialysate potassium concen-
tration to clinical outcomes have been mixed,7,11,12
although recent editorials recommend avoiding dial-
ysate potassium concentrations , 2 mEq/L, particu-
larly in patients with high predialysis serum
potassium levels.6,14-18 The potential hazards of very
low (, 2 mEq/L) dialysate potassium concentrations
are triggered by larger removal of potassium during
HD causing intradialytic and postdialysis hypokale-
mia and often a rapid rebound of potassium levels
postdialysis, contributing to cardiac instability.30 In
our primary analysis comparing more common dial-
ysate potassium prescriptions, we found a similar risk
for adverse events; any differences were modest and
unlikely to be clinically important. The comparison of
all-cause mortality risk using dialysate potassium
concentrations $ 3.0 versus 2.0 to 2.5 mEq/L was
qualitatively similar to a previous DOPPS publica-
tion,20 which found an 8% increased risk for mortality
for the lower dialysate potassium concentration.
Jadoul et al20 observed a stronger association using
instrumental variable analyses, but a larger sample
size of more contemporary patients and small differ-
ences in methodology used in the current study
combined to result in instrumental variable analyses
more consistent with the standard methods.
Rather than considering serum and dialysate po-
tassium concentrations as independent risk factors,
minimizing the potassium gradient, deﬁned as the
difference between the patient’s predialysis serum
potassium level and dialysate potassium concentra-
tion, is often recommended.7,31,32 However, a naive
analysis of gradient potassium and mortality would be
driven by serum potassium level because variability
in gradient potassium is driven largely by serumAm J Kidney Dis. 2017;69(2):266-277potassium and high serum potassium level is associ-
ated with worse outcomes. Further, an analysis of
gradient potassium adjusted for serum potassium level
is identical to an analysis of dialysate potassium
concentration adjusted for serum potassium level. To
more precisely test whether a large potassium gradient
is associated with adverse events, we instead inves-
tigated whether a lower dialysate potassium concen-
tration (2.0 mEq/L) would be particularly harmful in
combination with a high serum potassium level
(. 6.0 mEq/L, resulting in a gradient potassium
. 4.0 mEq/L), but found minimal association in this
subgroup of potentially high-risk patients (Table 5).
After accounting for confounding by indication, we
observed only a minimal effect of dialysate potassium
concentration on predialysis serum potassium level.
Although lower dialysate potassiumconcentration leads
to lower serum potassium levels throughout and
immediately following theHDsession,10,30,33wewould
not expect to observe a strong association with serum
potassium levels measured predialysis, 2 to 3 days after
exposure to dialysate potassium. Thus interventions to
avoid chronic hyperkalemia, such as prescription of
potassium-binding medications and/or education to
reduce dietary potassium intake, may be more effective
than lowering dialysate potassium concentrations.
Strengths of our study include a very large sample
size, capture of representative patients in typical care
settings, detailed data collection of potential con-
founders, causes of death and hospitalization, and
considerable variation in practice patterns, which
facilitated analyses.
Our study also has several limitations. First,
because of its observational design, this study cannot
estimate the causal impact of serum potassium level
and dialysate potassium concentration on risk for
adverse events. Although adjustment for a compre-
hensive set of potential confounders in both standard275
Karaboyas et alCox regression and instrumental variable analyses
helps mitigate bias, residual confounding may remain.
Second, our analysis of the arrhythmia composite
outcome is limited by missingness and potential
misclassiﬁcation of the causes of death and hospital-
ization; our large sample is generally considered a
strength, but in this case, smaller studies may be able
to characterize these causes more uniformly. Third,
we did not have data for postdialysis serum potassium
levels. Because the association between potassium
level and adverse events may be mediated by post-
dialysis serum potassium level, these measurements
could have informed these analyses. Finally, only
prescribed dialysate potassium information was
available; in cases in which the patient may be indi-
vidualized to a dialysate potassium concentration that
differs from the prescribed dialysate potassium con-
centration for each HD session based on predialysis
serum potassium measurement, our data do not cap-
ture the precise dialysate potassium concentration
administered. This may be especially problematic in
cases in which the dialysate potassium concentration
administered during the treatment directly preceding
an arrhythmic event differed from the standing pre-
scription. Similarly, dialysate potassium proﬁling, the
varying of dialysate potassium concentration during a
single HD session,31,32,34 was not captured in the
DOPPS and thus we cannot calculate its prevalence or
speculate on its effect on clinical outcomes.
Despite the limitations, these ﬁndings have
important implications for dialysate potassium pre-
scribing practices and future research. We did not ﬁnd
evidence supporting a clinically meaningful differ-
ence in mortality or arrhythmias comparing dialysate
potassium concentrations of 3.0 versus 2.0 mEq/L at
any level of predialysis serum potassium and thus
cannot provide a recommendation for any immediate
changes in practice. Long term, our results support
equipoise for future research of an easily modiﬁable
practice pattern in a randomized setting. As previ-
ously reported, high predialysis serum potassium
level was associated with increased risk for adverse
events. However, we observed minimal association
between dialysate potassium concentration and serum
potassium measured before dialysis. In combination,
these results suggest that approaches other than
altering dialysate potassium concentration (eg, edu-
cation on dietary potassium sources and prescription
of potassium-binding medications) may merit further
attention to reduce risks associated with high serum
potassium levels.
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